# A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas

> **NCT02130869** · PHASE1 · COMPLETED · sponsor: **St. Jude Children's Research Hospital** · enrollment: 8 (actual)

## Conditions studied

- Neuroblastoma
- Lymphoma
- High-risk Tumor

## Interventions

- **BIOLOGICAL:** CD133+ selected autologous stem cell infusion
- **BIOLOGICAL:** IL-2
- **BIOLOGICAL:** hu14.18K322A
- **DRUG:** Busulfan
- **DRUG:** Melphalan
- **BIOLOGICAL:** GM-CSF
- **DRUG:** Bendamustine
- **DRUG:** Etoposide
- **DRUG:** Cytarabine
- **DRUG:** Carboplatin
- **DEVICE:** Haploidentical natural killer cell infusion
- **BIOLOGICAL:** G-CSF
- **DRUG:** Etoposide phosphate
- **DEVICE:** CliniMACS

## Key facts

- **NCT ID:** NCT02130869
- **Lead sponsor:** St. Jude Children's Research Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-10
- **Primary completion:** 2017-12-20
- **Final completion:** 2017-12-20
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2017-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02130869

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02130869, "A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02130869. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*